Abstract Purpose: The ectopically expressed and deregulated fibroblast growth factor receptor 3 (FGFR3) results from a t(4;14) chromosomal translocation that occurs in f15 % of multiple myeloma (MM) patients and confers a particularly poor prognosis. This study assesses the antimyeloma activity of CHIR-258, a small-molecule inhibitor of multiple receptor tyrosine kinases that is currently in phase I trials, in a newly developed FGFR3-driven preclinical MM animal model. Experimental Design: We developed an orthotopic MM model in mice using a luciferaseexpressing human KMS-11-luc line that expresses mutant FGFR3 (Y373C). The antimyeloma activity of CHIR-258 was evaluated at doses that inhibited FGFR3 signaling in vivo in this FGFR3-driven animal model. Results: Noninvasive bioluminescence imaging detected MM lesions in nearly all mice injected with KMS-11-luc cells, which were mainly localized in the spine, skull, and pelvis, resulting in frequent development of paralysis. Daily oral administration of CHIR-258 at doses that inhibited FGFR3 signaling in KMS-11-luc tumors in vivo resulted in a significant inhibition of KMS-11-luc tumor growth, which translated into a significant improvement in animal survival. Conclusions: Our data provide a relevant preclinical basis for clinical trials of CHIR-258 in FGFR3-positive MM patients.
Multiple myeloma (MM), a B-cell neoplasm characterized by clonal expansion of plasma cells in the bone marrow, remains a fatal hematologic malignancy due to the development of intrinsic and acquired drug resistance, despite the introduction of conventional high-dosage chemotherapy. In 50% of intramedullary MM patients, a chromosomal translocation involving the immunoglobulin heavy chain (IgH) locus on chromosome 14q32 is an early event in the development of this disease (1) . The IgH locus can recombine with several partners, including the 4p16.3 locus, resulting in aberrant expression of fibroblast growth factor receptor 3 (FGFR3; refs. 2, 3). The ectopically expressed and deregulated FGFR3 resulting from a t(4;14) chromosomal translocation, which occurs in f15% of MM patients and confers a particularly poor prognosis in the clinic, provides an attractive therapeutic target for MM (4, 5) . Deregulated FGFR3 signaling has been shown to be oncogenic (4, 6, 7) . Additionally, the bone marrow microenvironment, where MM cells preferentially home and grow, plays a crucial role in MM cell growth and survival and in developing resistance to conventional and novel therapies for MM. It has been shown that angiogenic factors, including vascular endothelial growth factor (VEGF) and basic fibroblast growth factor, are expressed and secreted by MM cells and contribute to myeloma-bone marrow neovascularization (8) . Therefore, selective agents that directly target FGFR3-positive MM cells and target the interactions between myeloma cells and the bone marrow microenvironment offer a potential opportunity to treat MM patients with FGFR3 dysregulation.
CHIR-258 is a small-molecule inhibitor that targets multiple receptor tyrosine kinases, including VEGF receptor 2 and platelet-derived growth factor receptor (IC 50 values of f20 nmol/L in kinase assays) and FGFR3 (IC 50 value of f5 nmol/L in kinase assays; ref. 9) . CHIR-258 has been shown to inhibit FGFR3 autophosphorylation and cell proliferation in human myeloma cell lines expressing wild type or activated mutant FGFR3 (10) . CHIR-258 has potent anticancer activity in a broad range of preclinical xenograft models, including a s.c. implanted MM model (9 -11) .
Development of a target-driven, disease-relevant MM preclinical model is of particular interest for understanding the pathobiology of MM and for potential drug development.
severe combined immunodeficient (SCID) mice in which the disease pathology mimics the myeloma cell growth and interaction with the bone marrow microenvironment found in the human disease (12 -16) . Although these models have shed light on crucial aspects of myeloma biology, limitations have been encountered at a practical level.
In this study, we have developed an orthotopic MM model using human KMS-11 cells expressing mutant FGFR3 (Y373C; ref. 17) engineered to stably express luciferase. Bioluminescence imaging (BLI) was used to noninvasively monitor inhibition of the in vivo growth of MM tumors after treatment with CHIR-258. Serial comprehensive monitoring of growth of metastatic lesions was successfully captured by BLI with this model. Nearly all mice inoculated i.v. with KMS-11-luc MM cells were found to develop MM lesions, which were mainly localized in spine, skull, and pelvis, resulting in frequent development of paralysis. Daily oral administration of CHIR-258 at doses that were shown to inhibit the FGFR signaling pathway in KMS-11-luc tumors in vivo resulted in a significant inhibition of tumor growth and dissemination, as detected by serial BLI. Furthermore, the antitumor activity of CHIR-258 translated to a significant improvement in survival compared with treatment with the drug vehicle alone. These studies provide further scientific rationale for clinical trials of CHIR-258 in FGFR3-expressing MM patients.
Materials and Methods
Cell line. Stable luciferase expression was achieved by retroviral transfection of the pGC-gfp/luc vector (gift of G.P. Nolan, Stanford University) into the human MM cell line KMS-11. Cells were analyzed and sorted for a high expressing GFP + pool of KMS-11-luc cells used in this report. KMS-11-luc cells were cultured using standard techniques in Iscove's medium supplemented with 10% fetal bovine serum, 2 mmol/L L-glutamine (Mediatech, Inc., Herndon, VA), and maintained routinely in a humidified chamber at 37jC and 5% carbon dioxide. When grown under conditions for serum deprivation, 0.1% bovine serum albumin (Sigma-Aldrich, St. Louis, MO) was added to the medium.
In vitro immunoprecipitation and Western blot analysis. KMS-11-luc cells were grown in Iscove's medium containing 0.1% bovine serum albumin for 40 hours before treatment with CHIR-258 for 3 hours. Cells were then lysed in radioimmunoprecipitation assay buffer [20 mmol/L Tris (pH 8); 135 mmol/L NaCl; 2 mmol/L EDTA (pH 8); 10% glycerol; 1% Triton X-100; 0.1% SDS; 0.1% sodium deoxycholate] containing protease and phosphatase inhibitor cocktails (Roche Applied Science, Indianapolis, IN; Sigma-Aldrich) and 1 mmol/L phenylmethylsulfonyl fluoride for 1 hour at 4jC. Lysates were then centrifuged at 14,000 rpm for 10 minutes and resulting supernatants were collected for protein concentration determination using the BCA Protein Assay kit according to instructions from the manufacturer (Pierce Chemical Company, Rockford, IL).
To detect phosphorylated (phospho-) FGFR3 levels, 0.5 mg total protein lysate was immunoprecipitated with 10 AL of an affinity-purified anti-rabbit polyclonal antibody against phospho-FGFR (Chiron Corporation, Emeryville, CA) in radioimmunoprecipitation assay buffer containing inhibitor cocktails at 4jC for 2 to 3 hours and recovered with protein G-sepharose (GE Healthcare, Piscataway, NJ) for 1 hour at 4jC. Immunoprecipitates were electrophoresed on Novex Tris-Glycine SDS-PAGE gels (Invitrogen Corporation, Carlsbad, CA) and protein transferred to 0.45 Am nitrocellulose membranes (Invitrogen). Phospho-FGFR3 was detected by immunoblot using an antibody specific to FGFR3 (Santa Cruz Biotechnology, Santa Cruz, CA). Phospho-FGFR substrate 2 (FRS2) and total FRS2 were detected by immunoblot from 50 to 100 Ag of total protein lysates with an anti-phospho-FRS2 antibody (Cell Signaling, Danvers, MA) and anti-total FRS2 antibody (Santa Cruz Biotechnology). Phosphorylated and total extracellular signalregulated kinase 1/2 (ERK1/2) were detected by immunoblot from 50 to 100 Ag of total protein lysates with an anti-phospho-ERK1/2 antibody (Cell Signaling) and anti-total ERK1/2 antibody (Cell Signaling). Immunohistochemical analysis showed FGFR3 expression of KMS-11-luc MM cells (Â100 and Â400 magnification; B). 500 mm 3 were treated with a single oral administration of CHIR-258 at indicated doses or its vehicle (citrate buffer) for measurement of phosphorylated levels of FGFR3, FRS2, and ERK1/2. Tumors were collected from euthanized mice at 4, 8, 16, and 24 hours postdose. The resected tumors were immediately pulverized using a liquid nitrogen -cooled cryomortar and pestle and stored at À70jC until used. Pulverized tumors were later homogenized in cold radioimmunoprecipitation assay lysis buffer with protease and phosphatase inhibitors, as described above. The lysates were centrifuged at 14,000 rpm for 10 minutes at 4jC and the resulting lysates were then centrifuged a second time. The resulting supernatants were collected and the amount of protein in each lysate was immediately determined using the BCA Protein Assay (Pierce Chemical). Immunoprecipitates and total protein lysates were analyzed by Western blot analysis with primary antibodies, as described above.
In vivo orthotopic MM model development. Female SCID-Beige mice received whole-body irradiation at 3 Gy (3.2 minutes), 1 day before tail vein injection of 0.5 to 10 million KMS-11-luc cell in 0.1 mL HBSS. On designated days postinoculation, KMS-11-luc cells were detected in the mice using the IVIS imaging system (Xenogen Corporation, Alameda, CA). For imaging, mice were injected i.p. with 150 mg/kg luciferin (Xenogen), followed by anesthetization with isoflurane. Ten minutes after injection of luciferin, mice were imaged using a charge coupled device camera in the IVIS imaging system to evaluate the bioluminescence of cancer cells in the animal. Briefly, a gray-scale image of the mice was captured, followed by an overlay of a bioluminescence map representing the spatial distribution of photons detected from cleaved luciferin in the cancer cells expressing luciferase. Signal intensity was quantified using a customized version of the IGOR Pro version 4.09A Software (WaveMetrics, Inc., Lake Oswego, OR) called Living Image version 2.50.2 (Xenogen). The sum of all detected photon counts from the dorsal and ventral imaging was determined.
CHIR-258 efficacy evaluation in orthotopic MM model. For efficacy studies, dosing was either initiated 2 days post-KMS-11-luc implantation (early-stage disease treatment, low tumor burden) or 25 days postimplantation (late-stage disease treatment, high tumor burden), as described in the figure legends. CHIR-258 or its vehicle were administered daily by oral gavage to the end of the study. Velcade (bortezomib; Millennium Pharmaceuticals, Cambridge, MA) was administered i.p. twice weekly at 0.5 mg/kg (18) . For evaluating treatment of late-stage disease, mice were grouped based on matching photon counts before initiation of the treatments. Differences in photon emission readings, a measure of bioluminescence in cancer cells, were determined using the IVIS imaging system once weekly throughout the studies. At experimental end points characterized primarily by hind limb paralysis, mice were humanely euthanized, with the remaining percentage of mice surviving plotted over time (Kaplan-Meier survival analysis). P values were calculated using the log-rank test (Prism 4.0 software) to assess differences between treated and control groups (P < 0.05 was considered significant).
KMS-11-luc histopathology and immunohistochemistry. Four-micrometer sections were prepared from decalcified, formalin-fixed, and paraffin-embedded mouse femurs. Histopathology of the femur sections was visualized by conventional H&E staining. For detection of FGFR3 protein, a rabbit polyclonal antihuman antibody (Santa Cruz Biotechnology) was used. A biotinylated anti-rabbit secondary antibody (The Jackson Laboratory, West Grove, PA) was also used in this detection assay. Slides were stained using an automated slide stainer and compatible ancillary reagents for 3,3 ¶-diaminobenzidine chromagen detection (Discovery XT, Ventana Medical Systems, Tucson, AZ).
Results
CHIR-258 reduces FGFR3 and downstream FRS2 and ERK 1/2 phosphorylation in KMS-11-luc cultured cells in vitro. The parental KMS-11 cell line was originally derived from an endstage myeloma patient who harbored a t(4;14) translocation resulting in ectopic expression of FGFR3 with a heterozygous gain-of-function FGFR3 gene mutation (Y373C; refs. 4, 17) . To develop a KMS-11 MM model of disseminated disease that could be monitored by BLI, a subclone was engineered to constitutively and stably express luciferase (KMS-11-luc). To characterize this subclone, cultured KMS-11-luc cells were treated with CHIR-258 while grown under serum deprivation or in the presence of 10% fetal bovine serum. Under serumstarved conditions, phospho-FGFR3 was evident in KMS-11-luc cells, indicating a degree of constitutive activation of the receptor due to its Y373C mutation. To verify the ability of CHIR-258 to inhibit FGFR3 kinase activity in this subclone, receptor phosphorylation was monitored by immunoprecipitation followed by Western blot analysis. As shown in Fig. 1 , CHIR-258 reduced either serum-starved or 10% fetal bovine serum -exposed FGFR3 phosphorylation levels at 1, 2.5, and 5 Amol/L concentrations.
FRS2 is an immediate downstream docking protein and substrate for the FGFR family, and FGFR-mediated signaling induces activation of the mitogen-activated protein kinase pathway, of which ERK1/2 are key effectors (19) . To examine the effect of CHIR-258 treatment on FGFR3 signaling events downstream of receptor activation, FRS2 and ERK1/2 phosphorylation levels were measured. As shown in Fig. 1 , CHIR-258 reduced phospho-FRS2 and phospho-ERK1/2 levels. These results provide in vitro evidence that the KMS-11-luc subclone expresses FGFR3 with constitutive activity, and that CHIR-258 inhibits FGFR3 activation and subsequent downstream signaling.
CHIR-258 inhibits FRS2 and ERK 1/2 phosphorylation in vivo. To determine the degree and duration of inhibition of FGFR3 signaling in vivo in the KMS-11-luc subclone, SCIDBeige mice bearing s.c. KMS-11-luc MM tumors were administered a single dose of CHIR-258 at 20, 50, and 100 mg/kg or its vehicle, and tumors were collected at 4, 16, and 24 hours postdose. Treatment with CHIR-258 resulted in a marked reduction in FGFR3, FRS2, and ERK1/2 phosphorylation levels compared with tumors from vehicle-treated mice (Fig. 2) . At 20 mg/kg, phospho-FGFR3 and phospho-FRS2 levels were significantly reduced and were completely inhibited after treatment with 50 and 100 mg/kg at the 4-hour time point (Fig. 2A) . A corresponding dose-dependent phospho-ERK inhibition by CHIR-258 was observed. Four hours after treatment with 20 mg/kg, phospho-ERK1/2 levels in tumors were reduced by approximately half, with the greatest reduction seen in tumors from the 100 mg/kg dosed group. The duration of inhibition was determined by monitoring the recovery of phospho-FRS2 (Fig. 2B) . Tumors from mice administered 20 and 50 mg/kg doses similarly showed strong inhibition up to 16 hours, with some recovery by 24 hours postdose. Taken together, these results provide direct pharmacodynamic evidence of inhibition of FGFR3 signaling by CHIR-258 at 20 mg/kg during most of the dosing interval of 24 hours.
Establishing an orthotopic KMS-11-luc MM model. To allow for serial monitoring of MM dissemination and growth in vivo, KMS-11-luc MM cells were injected into SCID-Beige mice via the tail vein at different densities (ranging from 0.5 Â 10 6 to 10 Â 10 6 per mouse), and the IVIS imaging system was used for external whole-body, real-time BLI. Before use in vivo, engineered KMS-11-luc cells were confirmed in vitro to homogeneously express high levels of luciferase, as monitored by the IVIS imaging system (data not shown). In vivo, the whole-body photon emission increased in a cell densitydependent manner. As inoculation of 10 million cells provided the most rapid disease onset, it was selected for subsequent efficacy studies (Fig. 3A) . Twelve days after Cancer Research.
on September 6, 2017. © 2006 American Association for clincancerres.aacrjournals.org Downloaded from inoculation of KMS-11-luc cells, whole-body imaging showed increased BLI signal, suggesting cell growth and possible MM lesions localized in extraskeletal regions, including lung, liver, and spleen. However, typical diffuse multiple skeletal lesions, including skull, pelvis, and spine, became the predominant lesions in the majority of mice, as seen in the BLI images in Figs. 3A and 4C. These lesions ultimately led primarily to hind limb paralysis with occasional significant body weight loss due to tumor burden, at which time mice were sacrificed. This was termed ''conditional survival.'' Histologic analysis of femurs collected from euthanized mice confirmed MM cell infiltration into bone marrow (Fig. 3B) . Immunohistochemical staining also verified FGFR3 expression in the KMS-11-luc MM cells growing in bone marrow. These results showed the feasibility of the orthotopic KMS-11-luc MM model for evaluating investigational agents for MM and specifically those targeting FGFR3.
CHIR-258 treatment significantly inhibited KMS-11-luc growth in the bone marrow and prolonged survival of mice. The antimyeloma efficacy of CHIR-258 was evaluated in this disseminated disease model of KMS-11-luc, with treatment administration initiated either during early disease stage (2 days after cell inoculation) or late disease stage (25 days after cell inoculation). In the early-stage disease model, mice were administered CHIR-258 orally at 20 mg/kg/d, the dose shown to inhibit FGFR3 signaling in vivo ( Fig. 2A and B) . Serial whole-body monitoring of photon emission from KMS-11-luc in mice was done once weekly. CHIR-258 administered at 20 mg/kg/d starting 2 days after cell inoculation had significant in vivo activity against KMS-11-luc MM xenografts, resulting in a 75% reduction in mean photon counts on day 41 (Fig. 4A and B) . This antimyeloma effect was clearly observed by comparison of the whole-body BLI from mice injected with KMS-11-luc treated with vehicle or CHIR-258, as shown in Fig. 4A-C . A significant delay of hind limb paralysis and enhanced survival of the mice were shown in the CHIR-258 -treated group compared with the vehicle cohort (P < 0.0001, log rank test; Fig. 4D ). After 3 months, five of nine mice treated with CHIR-258 remained alive with an overall healthy appearance. Due to the prolonged survival of mice treated with CHIR-258, the study was terminated at day 91 for practical considerations, and median survival in this group was not calculated. In contrast, the median survival in the vehicle-treated group was 55 days. These results showed that CHIR-258 antimyeloma activity translates into a significant improvement in animal survival. Histopathologic analysis from a satellite group of mice treated for 26 days with 20 mg/kg/d CHIR-258 compared with its drug vehicle showed nucleomegaly and multiple focal fibrosis, the latter presumably following resolution of the marked tumor cell necrosis from the CHIR-258 treatment (Fig. 4E) .
In the late-stage disease model, mice received CHIR-258 orally at 30 mg/kg/d starting 25 days postimplantation. A clinically approved MM treatment, Velcade, was included for comparison. Velcade was administered i.p. twice weekly at 0.5 mg/kg, reported to be within an efficacious dose range (18) . Despite the initiation of treatment at a late stage of disease, CHIR-258 significantly delayed the induction of hind limb paralysis and enhanced survival of the mice compared with the vehicle-treated cohort (P = 0.04; Fig. 5 ). The median survival in the vehicle-treated group was 41.5 days, whereas that of the CHIR-258 -treated group was 72 days. The median survival in the Velcade-treated group was intermediate at 54 days, which was not statistically different from vehicle (P = 0.29) using the log-rank analysis.
Discussion
The current studies focus on CHIR-258 inhibitory activity against FGFR3, a receptor tyrosine kinase family member that is reported to be expressed in f15% of newly diagnosed cases of MM. We have developed a novel orthotopic MM model in which FGFR3 is constitutively activated and showed that CHIR-258 strongly inhibits MM tumor growth and dissemination. Results from this study provide a biologically relevant rationale for clinical trials of CHIR-258 in FGFR3-positive MM patients.
Development of a target-specific preclinical MM model is of great interest for drug research and development. In this report, we present an in vivo orthotopic MM model in which multiorgan MM lesions developed after tail vein inoculation of human KMS-11-luc cells aberrantly expressing mutant FGFR3 (Y373C) stably engineered to express luciferase. Nearly all mice inoculated i.v. with KMS-11-luc MM cell developed lesions visualized by BLI, which were mainly localized in the spine, skull, and pelvis, resulting in frequent development of paralysis in this model. Immunohistochemical analyses confirmed FGFR3-positive cell penetration in the bone marrow of mice that developed the disease. The ability of the KMS-11-luc cells to colonize and grow in the bone marrow is consistent with the pathology in human MM disease. This model has provided a useful tool for preclinical evaluation for targeted MM therapy and potentially for further understanding the pathology of this disease.
Having an understanding of the degree and duration of FGFR3 signaling inhibition by a single dose of CHIR-258 directed our evaluation of CHIR-258 efficacy studies in the KMS-11-luc disseminated disease model. A single oral administration of CHIR-258 to mice harboring s.c. KMS-11-luc xenografts resulted in a reduction of phospho-FGFR3 and downstream phospho-FRS2, a key signaling molecule shown to directly interact with FGFR3, as well as downstream phospho-ERK1/2 levels in the tumors at 4 hours postdose. Even the lowest dose of 20 mg/kg suppressed phospho-FRS2 levels throughout the dosing interval of 24 hours used in the efficacy studies. A single administration of 20 or 50 mg/kg also resulted in a significant induction of the apoptosis marker cleaved poly(ADP)ribose polymerase in the s.c. tumors, peaking at 24 hours postdose (data not shown). Daily treatments of CHIR-258 resulted in a significant delay in tumor growth in the early-stage disease model and prolongation of survival in both early-and late-stage disease models. Furthermore, the efficacy appeared improved over the structurally and mechanistically distinct proteosome inhibitor Velcade, approved for the treatment of MM in humans, when administered to mice using a published dose and regimen (18) .
The efficacy of CHIR-258 in this orthotopic model of MM may be conferred in part by abrogation of the function of FGF, PDGF, and VEGF receptors in the supporting bone marrow stroma and vasculature. The plasma exposures of CHIR-258 achieved in this study (data not shown) were in the range previously shown to inhibit platelet-derived growth factor receptor h and VEGF receptor 2 and reduce microvessel density (9) . Platelet-derived growth factor receptor signaling on the pericytes supporting tumor vasculature is known to contribute to the process of neovascularization in growing tumors, as does VEGF receptor 2 signaling in endothelial cells (20) . Although we have not examined the contribution of platelet-derived growth factor receptor h and VEGF receptor 2 in these MM-derived tumors, both are targets of CHIR-258 that likely contribute to the efficacy observed in this study.
In summary, we have shown that daily oral administration of CHIR-258 at doses that inhibit the FGFR3 signaling pathway in KMS-11-luc tumors in vivo resulted in significant inhibition of MM disease, as detected by serial BLI. Furthermore, the antitumor activity of CHIR-258 translated into a significant improvement in the animal survival rate compared with treatment with the drug vehicle alone. Demonstration of CHIR-258 activity in this novel orthotopic MM model provides a relevant preclinical basis for the ongoing clinical trial of CHIR-258 in MM.
